WASHINGTON - The FDA is conducting its final review of a Points To Consider document on xenotransplants, which will elaborate on the draft guidelines covering transplantation of tissues and organs from animals to humans published in the Federal Register last week.

Philip Noguchi, director of FDA's division of cell and gene therapy, told BioCentury the Points To Consider document will go into much greater detail than the guidelines issued jointly by the FDA, the Public Health Service and the Centers for Disease Control.